| 78.87 -0.692 (-0.87%) | 04-02 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 95.92 | 1-year : | 112.04 |
| Resists | First : | 82.12 | Second : | 95.92 |
| Pivot price | 77.35 |
|||
| Supports | First : | 78.03 | Second : | 75.5 |
| MAs | MA(5) : | 78.01 |
MA(20) : | 77.53 |
| MA(100) : | 80.6 |
MA(250) : | 71.7 |
|
| MACD | MACD : | -0.6 |
Signal : | -1 |
| %K %D | K(14,3) : | 85.9 |
D(3) : | 67.6 |
| RSI | RSI(14): 51.4  |
|||
| 52-week | High : | 85.73 | Low : | 53.95 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PBE ] has closed below upper band by 17.0%. Bollinger Bands are 11.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 79.28 - 79.68 | 79.68 - 79.99 |
| Low: | 77.35 - 77.78 | 77.78 - 78.11 |
| Close: | 78.19 - 78.91 | 78.91 - 79.46 |
The Invesco Biotechnology & Genome ETF (Fund) is based on the Dynamic Biotech & Genome Intellidex Index (Index). The Fund will normally invest at least 90% of its total assets in the securities that comprise the Index. The Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The Index is comprised of securities of 30 US biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November.
Sat, 04 Apr 2026
Invesco Biotechnology & Genome ETF declares quarterly distribution of $0.0824 - MSN
Sun, 08 Mar 2026
Precision Trading with Invesco Nasdaq Biotechnology Etf (IBBQ) Risk Zones - news.stocktradersdaily.com
Wed, 11 Feb 2026
7 Best Biotech ETFs to Buy Now - U.S. News Money
Tue, 02 Dec 2025
Tema Oncology ETF (CANC) Passes $100m AUM, Among Top 3 2025 Healthcare ETFs - stocktitan.net
Thu, 02 Oct 2025
The Best Biotech ETFs to Buy - Kiplinger
Mon, 29 Sep 2025
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|